Cholinesterase inhibitors in the clinical management of Alzheimer's disease: Importance of early and persistent treatment

Journal of International Medical Research

Volumn 34, Issue 4, 2006, Pages 339-347

  Seltzer, B ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors (CHEIs); Donepezil; Galantamine; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; BRAIN BLOOD FLOW; CAREGIVER; CLINICAL TRIAL; COGNITION; DAILY LIFE ACTIVITY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; GLUCOSE METABOLISM; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LONG TERM CARE; MINI MENTAL STATE EXAMINATION; NEUROPROTECTION; NONHUMAN; QUALITY OF LIFE; REVIEW; SHORT COURSE THERAPY; SYMPTOM;

EID: 33748536688     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400401     Document Type: Review

References (45)

1. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
2. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al: The effects of donepezil in Alzheimer's disease - results from a multi-national trial. Dement Geriatr Cogn Disord 1999; 10: 237-244.
3. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
4. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268.
5. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293-303.
6. Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-1031.
7. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
8. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-638. [Published erratum appears in: BMJ 2001; 322: 1456.]
9. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-2276.
10. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445-1449. [Published erratum appears in BMJ 2001; 322: 405.]
11. Potki SG, Anand R, Hartman R, Veach J, Grossberg G: Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 713-720.
12. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD; Donepezil Study Group: Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427-433.
13. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-241.
14. Winblad B, Engedal K, Soininen H, Waldemar G, Verhey F, Wimo A: Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: results from a 1-year placebo-controlled study and two-year follow-up study [abstract]. Int Psychogeriatr 2003; 15 (Suppl. 2): 293-294.
15. Raskind M, Truyen L, Kershaw P: Long-term safety and tolerability of galantamine in Alzheimer's disease: an open-label extension with up to 54 months' exposure. In: Proceedings of the 16th Annual Meeting of the American Association for Geriatric Psychiatry. Bethesda: American Association of Geriatric Psychiatry, 2003; pp90-91.
16. Seltzer B, Zolnouni P, Nunez M, Kumar D, Goldman R, Ieni J, et al: Donepezil treatment benefits in early-stage Alzheimer's disease. J Am Geriatr Soc 2003; 51: S100-S101.
17. Bartus RT, Dean RL 3rd, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-417.
18. Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974; 30: 113-121.
19. Davis KL, Mohs RC, Morin D, Purohit DP, Perl DP, Lantz M, et al: Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999; 21: 1401-1406.
20. DeKosky ST, Ikononomovic MD, Styren SD, Beckett I, Wisniewski S, Bennett DA, et al: Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51: 145-155.
21. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160: 2003-2011.
22. Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, et al: Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001; 57: 930-932.
23. Staff RT, Gemmell HG, Shanks MF, Murray AD, Venneri A: Changes in the rCBF images of patients with Alzheimer's disease receiving donepezil therapy. Nucl Med Commun 2000; 21: 37-41.
24. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, et al: Donepezil HCI (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 2003; 11: 169-177.
25. 1-42 (CSF-Aβ42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 2003; 338: 159-163.
26. Akasofu S, Kosasa T, Kimura M, Kubota A: Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol 2003; 472: 57-63.
27. Zhou J, Fu Y, Tang XC: Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci Lett 2001; 306: 53-56.
28. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, et al: Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 2003; 306: 772-777.
29. 3H]MK-801 binding in rat cerebral cortex. Neurosci Lett 1999; 272: 21-24.
30. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al: Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495.
31. Rogers SL, Doody RS, Pratt RD, Ieni JR: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203.
32. Raskind MA, Peskind ER, Truyen L, Kershaw P, Domaraju CV: The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neural 2004; 61: 252-256.
33. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; "312" Study Group: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-488. [Published erratum appears in Neurology 2001; 57: 1942.]
34. Hughes CP, Berg L, Danziger LW, Cohen LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-572.
35. Callahan CM, Hendrie HC, Tierney WM: Documentation and evaluation of cognitive impairment in elderly primary care patients, Ann Intern Med 1995; 122: 422-429.
36. Geldmacher DS: Cost-effective recognition and diagnosis of dementia. Semin Neurol 2002; 22 63-70.
37. Boise L, Camicioli R, Morgan DL, Rose JH, Congleton L: Diagnosing dementia: perspectives of primary care physicians. Gerontologist 1999; 39: 457-464.
38. Johannsen P, Barcikowska M, Heun R, Holub R, Jakobsen S, Triau E, et al: Donepezil treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: results from a randomized placebo-controlled trial. J Neurol 2003; 250 (Suppl. 2): II/126.
39. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003; 51: 937-944.
40. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST: Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 72: 310-314.
41. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W: Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004; 161: 532-538.
42. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, et al: Donepezil MSAD Study Investigators Group: Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737-744.
43. Mastey V, Winblad B, Wimo A, Haglund A, Jacobson L, Miceli R, et al: Donepezil reduces the time caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with mild to moderate Alzheimer's disease. Am J Geriatr Psychiatry 2001; 49: S20.
44. Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G; AHEAD Study Group: Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 2003; 25: 1806-1825.
45. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al: AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-2115.